Phase 1/2 Study of Intravenous or Intrapleural Administration of a Serotype rh.10 Replication Deficient Adeno-associated Virus Gene Transfer Vector Expressing the Human Alpha-1 Antitrypsin cDNA to Individuals With Alpha-1 Antitrypsin Deficiency

Trial Profile

Phase 1/2 Study of Intravenous or Intrapleural Administration of a Serotype rh.10 Replication Deficient Adeno-associated Virus Gene Transfer Vector Expressing the Human Alpha-1 Antitrypsin cDNA to Individuals With Alpha-1 Antitrypsin Deficiency

Recruiting
Phase of Trial: Phase I/II

Latest Information Update: 01 Aug 2018

At a glance

  • Drugs ADVM 043 (Primary) ; ADVM 043 (Primary)
  • Indications Alpha 1-antitrypsin deficiency
  • Focus Adverse reactions; First in man
  • Acronyms ADVANCE
  • Sponsors Adverum Biotechnologies
  • Most Recent Events

    • 01 Aug 2018 According to an Adverum Biotechnologies media release, based on a review of the preliminary safety data from patients in Cohort 2, the independent data monitoring co mmittee (DMC) recommended dose escalation to Cohort 3, and the first patient was dosed with a single administration of ADVM-043 in late July 2018.
    • 01 Aug 2018 According to an Adverum Biotechnologies media release, the company expects to report preliminary data from patients in cohorts 1 through 3 in this trial by the end of this year.
    • 03 May 2018 According to an Adverum Biotechnologies media release, In late April 2018, first patient had been dosed in Cohort 2.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top